Medison Pharma Ltd.
10 Hashiloach Street
P.O. Box 7090
Petach Tikva
49170
Tel: 972-3-9250250
Fax: 972-3-9225740
Website: http://www.medisonpharma.com/
Email: medison@medison.co.il
32 articles about Medison Pharma Ltd.
-
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
1/8/2024
Medison Pharma announced their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo®, a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.
-
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
11/13/2023
Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay™ for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, a progressive and life-threatening liver disease.
-
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
3/9/2023
Alnylam Pharmaceuticals, Inc. and Medison Pharma have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.
-
Sarah Otten Joins Medison Pharma as VP, GM Americas Region
1/9/2023
Medison Pharma, a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is proud to announce the joining of Sarah Otten, in the role of VP, GM of Medison's Americas Region.
-
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
11/9/2022
Medison Pharma announced the addition of South and Central America and the Caribbean markets to its multi-territorial agreement with Immunocore Holdings plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease.
-
Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients
8/22/2022
Hansa Biopharma AB today announced that the Polish Ministry of Health has agreed to include Idefirix® on its reimbursement list for desensitization of highly sensitized patients prior to kidney transplantation.
-
Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
8/16/2022
Medison Pharma announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in Canada and Israel.
-
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
8/10/2022
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc., along with partner Medison Pharma announced that the State of Israel Ministry of Health has approved NULIBRY® for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency Type A.
-
Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma
6/8/2022
Medison Pharma is pleased to announce the approval of KIMMTRAK® by Health Canada and Therapeutics Goods Administration for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.
-
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
6/6/2022
Medison Pharma announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries.
-
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
5/23/2022
Medison Pharma today announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings plc.
-
Victor Papamoniodis Joins Medison Pharma as VP International Markets
1/20/2022
Medison is proud to announce the joining of Victor Papamoniodis in the newly created position of VP International Markets.
-
Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa's desensitization treatment for kidney transplant in Central Eastern Europe and Israel
12/7/2021
Hansa Biopharma AB and Medison Pharma announce a multiregional agreement for Medison to commercialize Hansa's desensitization treatment for kidney transplants in Central Eastern Europe and Israel.
-
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
6/7/2021
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
-
Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe
6/15/2020
Medison Pharma Trading AG, a fully owned subsidiary of Medison Pharma Ltd., and Alpha Tau Medical Ltd., the developer of a breakthrough alpha-radiation cancer therapy "Alpha DaRT," are pleased to announce an exploratory collaboration in the oncology field in Central and Eastern Europe.
-
Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC™ ODT In Israel
4/16/2020
- Biohaven and Medison Pharma's partnership will bring NURTEC ODT, the first oral, quick-dissolve, calcitonin gene related peptide (CGRP) antagonist to patients in Israel - Registration in Israel based upon Biohaven's NURTEC ODT approval in the US
-
BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A
12/18/2019
BridgeBio Pharma, Inc. and Medison Pharma Ltd. have entered into an exclusive license agreement under which Medison received rights from Origin to distribute, market, sell and otherwise commercialize Origin’s drug product known as fosdenopterin in Israel..
-
Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Qualified Nominees at Upcoming Annual Meeting
4/29/2019
Failures at Knight have been exposed by multiple, independent third parties
-
Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics
4/25/2019
ISS Notes "Stark" Underperformance, Recommends Election of New Independent Directors and for Knight Shareholders to Vote on the GOLD Proxy Card
-
Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX (neratinib) in Israel
1/30/2018
Puma Biotechnology, a biopharmaceutical company, and Medison Pharma Ltd. Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison will commercialize NERLYNX® (neratinib) in Israel.